🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Fantastic to host the stellar Brian Rini, MD Uromigos in Seattle for Grand Rounds. We started with delicious dinner & great company Evan Hall Lisa Tachiki, MD Dimitra R. Bakaloudi MD, MS, MPA #Tykodi reviewed RCC, clinical research, leadership Fred Hutch Cancer Center Tom Powles @BhatiaS_MD Mazyar Shadman, MD MPH OncoAlert

Cost is checkpoint inhibitor prohibitive for access to these drugs- Lisa Tachiki, MD of Fred Hutch Cancer Center #SCHD23 @BhatiaS_MD Beyond Trauma Foundation Rahul Banerjee, MD, FACP

The cost of immune checkpoint inhibitors: $170,000 per patient per year. Less than 5% of eligible patients in LMIC are able to afford/access ICIs. Dr Lisa Tachiki of Fred Hutch Cancer Center discusses the ways to expand ICI access globally at #SCHD2023

#SCHD23 learned a ton from my co-panelists Lisa Tachiki, MD Hiba Khan MD MPH Krishna Komanduri, MD, FASTCT - some of these discussed ideas about de-escalating Tx dose/frequency will change the world some day! Thanks Beyond Trauma Foundation for inviting us and humoring my toddler ⚽️ analogy to drug development…

Fantastic Brian Rini, MD talk #AUA23 on nccRCC! Biomarker development & clinical trials remain essential! Nice shout out to Sumanta K. Pal, MD, FASCO PAPMET trial & launched SWOG Cancer Research Network 2200 trial & data on savolitinib Toni Choueiri, MD OncoAlert Neeraj Agarwal, MD, FASCO Society of Urologic Oncology Kidney Cancer Evan Hall Lisa Tachiki, MD

Congratulations @BhatiaS_MD on your distinguished faculty award! Well deserved! Thank for you hosting such a beautiful gala for such an important cause! Beyond Trauma Foundation Binay Shah, MD, MHA

Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Tom Powles Robert Motzer MD Hans Hammers

My colleague Hiba Khan MD MPH gave a meaningful talk ASCO this morning, highlighting a higher risk for mortality in patients who experience adverse financial events. It's also interesting to see the risk of death among common cancer types.

Thank you @BhatiaS_MD Evan Hall Paul Nghiem for your mentorship on this project and to all our coauthors for your work! So happy to be able to share our experience through this manuscript!!

Comprehensive discussion from #ScottTykodi Fred Hutch Cancer Center on 1st line metastatic #kidneycancer OncLive SOSS! Always helpful and thoughtful overview on data &patient selection. Petros Grivas Lisa Tachiki, MD Evan Hall #EvanYu KCCure Kidney Cancer KidneyCAN

And finally… Evan Hall Fred Hutch Cancer Center with update on refractory #kidneycancer OncLive SOSS, focusing on cabozantinib & belzutifan data. Another one to follow! Kidney Cancer KCCure KidneyCAN Petros Grivas Lisa Tachiki, MD #EvanYu

Every dose of an #ImmuneCheckpointInhibitor takes time and money. A new study from Lisa Tachiki, MD, @BhatiaS_MD and others shows that reducing the frequency of #ICI doses can save patients and the health care system time and money. bit.ly/3uU0U9n

Every dose of an #ImmuneCheckpointInhibitor takes time and money. A new study from Lisa Tachiki, MD, @BhatiaS_MD and others shows that reducing the frequency of #ICI doses can save patients and the health care system time and money. bit.ly/3uU0U9n

Suzzanne Lacey's stage 4 #kidneycancer diagnosis was no match for a potent blend of #immunotherapy, including a unique approach to reduced-frequency dosing. “It worked for her,” said Lacey's oncologist, Evan Hall. bit.ly/3PcRdtV

It is out ! OncoAlert Tom Powles

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ASCO24 for #Melanoma This List Curated by: #OncoAlertAF Leads : Annie Wong 黃毅敏 🇳🇿 Gil Morgan, MD 🇺🇸 and OncoAlert #Melanoma Faculty Allison Betof Warner, MD, PhD 🇺🇸 TOP 11 Abstracts Neoadjuvant

My top themes of #ASCO24 for #kidneycancer, #prostatecancer, #bladdercancer, & #DevelopmentalIO -- scratches only the surface of the bountiful harvest of ASCO trials!! Looking forward to seeing/hearing from colleagues from around the world ASCO ESMO - Eur. Oncology OncoAlert